CN1555814A - A kind of propolis active ingredient extraction method and application - Google Patents
A kind of propolis active ingredient extraction method and application Download PDFInfo
- Publication number
- CN1555814A CN1555814A CNA2004100258363A CN200410025836A CN1555814A CN 1555814 A CN1555814 A CN 1555814A CN A2004100258363 A CNA2004100258363 A CN A2004100258363A CN 200410025836 A CN200410025836 A CN 200410025836A CN 1555814 A CN1555814 A CN 1555814A
- Authority
- CN
- China
- Prior art keywords
- propolis
- extract
- water
- present
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000241413 Propolis Species 0.000 title claims abstract description 71
- 229940069949 propolis Drugs 0.000 title claims abstract description 71
- 239000004480 active ingredient Substances 0.000 title claims abstract description 10
- 238000000605 extraction Methods 0.000 title description 4
- 239000000284 extract Substances 0.000 claims abstract description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 21
- 210000004351 coronary vessel Anatomy 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 239000000262 estrogen Substances 0.000 claims description 5
- 229940011871 estrogen Drugs 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 238000000247 postprecipitation Methods 0.000 claims description 2
- 239000000047 product Substances 0.000 claims 2
- 239000003075 phytoestrogen Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 50
- 239000001103 potassium chloride Substances 0.000 description 25
- 235000011164 potassium chloride Nutrition 0.000 description 25
- 230000000694 effects Effects 0.000 description 18
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 14
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 8
- 239000001110 calcium chloride Substances 0.000 description 8
- 229910001628 calcium chloride Inorganic materials 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 7
- 229940123921 Nitric oxide synthase inhibitor Drugs 0.000 description 7
- 229960000905 indomethacin Drugs 0.000 description 7
- 229960000907 methylthioninium chloride Drugs 0.000 description 7
- 239000000236 nitric oxide synthase inhibitor Substances 0.000 description 7
- 229960003712 propranolol Drugs 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000003511 endothelial effect Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- 238000003287 bathing Methods 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 150000002212 flavone derivatives Chemical class 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 241000282894 Sus scrofa domesticus Species 0.000 description 2
- 208000006906 Vascular Ring Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及一种蜂胶中有效成分的提取方法，及这种有效成分的用途。更为确切讲，本发明涉及提取蜂胶中水溶性成分的方法和所提出的蜂胶中水溶性成分的用途。本发明的方法是将蜂胶用水进行提取。本发明的用途是指用本发明的方法所得到的蜂胶中水溶性提取物在制备冠状动脉舒张药物中的应用，和在制备植物雌激素类药物中的应用。The invention relates to a method for extracting active ingredients in propolis and uses of the active ingredients. More precisely, the present invention relates to a method for extracting water-soluble components of propolis and the proposed use of the water-soluble components of propolis. The method of the invention is to extract the propolis with water. The use of the present invention refers to the application of the water-soluble extract in propolis obtained by the method of the present invention in the preparation of coronary artery relaxation drugs, and the application in the preparation of phytoestrogen drugs.
Description
Technical field
The present invention relates to the extracting method of active ingredient in a kind of propolis, and the purposes of this active ingredient.More exactly, the present invention relates to extract the purposes of water-soluble components in the method for water-soluble components in the propolis and the propolis that proposed.
Background technology
Propolis is the resin secretions and the Cera Flava of Apis herborization, through chewing a kind of resinoid that modulation forms.Composition is very complicated in the propolis, and both at home and abroad to the chemical composition of propolis, biological agent, pharmacological action have a lot of research reports in recent years.It is antibiotic to discover that propolis has, antiviral, antiulcer, antiinflammatory, local anesthesia, blood pressure lowering, effects such as enhancing immunity.For active ingredient in the propolis, concentrate on organic solutions such as ethanol and ether in the prior art and extract, perhaps extract with high concentration organic solution soluble in water.As disclosed content in the Chinese invention patent 97111643.1.This patent adopts acetone, or acetic acid, or ethanol, or methanol, or isopropyl alcohol, perhaps with the active ingredient 3-[4-3 in the mixture extraction propolis of aforementioned solvents, and 5 hydroxyls-(two methyl-2 cyclobutenyls of 3-) phenyl]-2-acrylic acid, be used for anticorrosion, hair growth promoting and anticancer.In the prior art propolis extracted with non-organic solution and do not appear in the newspapers.
Summary of the invention
First purpose of the present invention provides a kind of water-soluble components method of extracting from propolis; Second purpose of the present invention is the purposes of the water-soluble components extracted from propolis of open usefulness method of the present invention.
Method of the present invention is that the propolis water is extracted.
The present invention more specifically method for optimizing is that propolis is pulverized, and water extracts again, and extracting solution is got its supernatant through centrifugal or abundant post precipitation, again with the supernatant lyophilizing.
Purposes of the present invention is meant with application and the application in preparation plant estrogens medicine of water solubility extract in the resulting propolis of method of the present invention in preparation coronary artery diastole medicine.
Extracting method of the present invention is very simple, and extraction cost is low.Propolis extract after the inventive method is handled is formed simple.Can also continue after adopting method of the present invention to handle therefore can make full use of the propolis resource with other active ingredient in the prior art extraction propolis.In addition, extract of the present invention can be used for preparing coronary artery diastole medicine, does not appear in the newspapers in this point prior art.Extract of the present invention is used for preparing the application of plant estrogens medicine, for the production of estrogens medicine provides new approach and raw material sources.
Description of drawings
Fig. 1 is the thin slice scan result of Flavonoid substances in the propolis extract.
Fig. 2 is that propolis extract concentration of the present invention is to direct diastole effect curves coronarius.
Fig. 3 is that propolis extract concentration of the present invention is to the pre-shrunk coronary artery inhibitory action of potassium chloride curve.
Fig. 4 is a nitric oxide synthase inhibitor activity, dispels coronary artery endothelial, methylene blue, and propranolol and indomethacin are to the direct diastole function influence of propolis extract of the present invention curve.
Fig. 5 is a nitric oxide synthase inhibitor activity, dispels coronary artery endothelial, methylene blue, propranolol and indomethacin to propolis extract of the present invention to the pre-shrunk inhibiting influence curve coronarius of potassium chloride.
Fig. 6 is the influence of propolis extract of the present invention to porcine coronary potassium chloride shrinkage curve.
Fig. 7 is the influence of propolis extract of the present invention to porcine coronary calcium chloride shrinkage curve.
The specific embodiment
The result of the test of following detailed explanation method of the present invention and associated uses.
One, propolis extracting method
Get fresh propolis, pulverize and be placed on distilled water (W/W=1: 20) under room temperature, stirred 48 hours; Filter; Filtering residue adds water and extracts repeatedly, filters; Merging filtrate, 15, under the 000rpm condition centrifugal 60 minutes;
Merge supernatant; After handling, lyophilizing gets the water-soluble bee glue composition.
After measured, the water-soluble bee glue that is extracted contains three kinds of flavone components, referring to accompanying drawing 1.Fig. 1 is the result of flavone thin slice scan under visible wavelength in the propolis water extract, and used developer is ferric chloride-alcoholic solution of 5%.
Two, propolis extract purposes of the present invention research
Experimental technique and condition:
Get the Cor Sus domestica of just having slaughtered from pig slaughtering factory and exist side by side soon that Cor Sus domestica places 0 ℃ normal saline, be transported to laboratory then immediately.At room temperature the pig left anterior descending coronary artery is cut and places the Krebs liquid of the carbon dioxide that is connected with 95% oxygen and 5% from cardiac muscle, temperature remains on 37 ℃.Carefully wipe out fat and its hetero-organization thereof of being attached on the arteria coronaria.Being cut into length then is the long coronary artery ring of 4-5mm.Immediately arterial ring is placed 10ml glass bath pipe with two parallel stainless hook levels, bathe in the pipe and contain Krebs liquid, it consists of (mM) NaCl 118, and KCl 4.7, NaH
2PO
41.2, MgCl
21.2, NaHCO
315.4, CaCl
22.5 and glucose 11.5, and continue to feed 95%O
2And 5%CO
2Mist, temperature remains on 37 ℃ in whole experiment.Preload gives 2g.Blood vessel produces tension force and is recorded in computer by pressure receptor (JH-2) with BL-410E biotic experiment system.
1, the propolis water extract is to direct effect coronarius
The porcine coronary ring hatched 90 minutes in bathing pipe after, again the propolis water extract is added the balneation pipe successively by the 0.316-100ug/ml variable concentrations, normal saline with equivalent adds another group porcine coronary ring at the bath pipe of another similarity condition simultaneously, as blank contrast experiment.Observation experiment result, result show that the propolis water extract can dose-dependent diastole coronary artery EC50=(75.35 ± 1.24) ug/ml (n=8).Show directly diastole coronary artery of propolis water extract, its maximum diastolic rate reaches 56.33%, referring to accompanying drawing 2.NS is the normal saline group among the figure, and WEP is a propolis water extract group.
2, the propolis water extract is to the pre-shrunk effect coronarius of potassium chloride
The porcine coronary ring hatched 90 minutes in bathing pipe after, add KCl (40mM) preshrinking coronary artery, after 15 minutes the propolis water extract is added the balneation pipe successively by the variable concentrations of 0.316-100ug/ml, normal saline with equivalent adds another group porcine coronary ring at the bath pipe of another similarity condition simultaneously, as blank contrast experiment.Observation experiment result, result show that the propolis water extract can dose-dependent diastole coronary artery IC50=(65.11 ± 1.72) ug/ml (n=8).Show that propolis can effectively suppress the contraction that causes because of potassium chloride, its maximum diastolic rate reaches 64.77%, referring to accompanying drawing 3.NS is the normal saline group among the figure, and WEP is a propolis water extract group.
3, nitric oxide synthase inhibitor activity is dispeled coronary artery endothelial, methylene blue, and propranolol and indomethacin are to the influence of propolis water extract diastole effect
Prepare coronary artery and before being cut to vascular ring, wipe blood vessel endothelium gently, to measure of the diastole effect of propolis water extract it with cotton swab.
The coronary blood pipe ring of not dispeling coronary artery endothelial is tested its function with Kallidin I, think that after tested the good vascular ring of endothelial function is as carrying out the experiment to the influence of propolis water extract diastole effect of nitric oxide synthase inhibitor activity, methylene blue, propranolol and indomethacin.
With nitric oxide synthase inhibitor activity (10
-4M), methylene blue (10
-5M), propranolol (10
-5M) and indomethacin (10
-5M) adding propolis water extract (100ug/m1) 15 minutes before respectively, perhaps add and added the balneation pipe before in 15 minutes at potassium chloride (40mM), the experimental group that adds potassium chloride also adds the balneation pipe with propolis water extract (100ug/ml) again adding potassium chloride after 15 minutes.Test result shows, nitric oxide synthase inhibitor activity, dispel endothelium and methylene blue and all can significantly lower the propolis water extract, or the propolis water extract is had obvious suppression effect (all P values are all less than 0.05) to the diastole effect of the pre-shrunk arteria coronaria of potassium chloride direct diastole effect coronarius; Propranolol and indomethacin then do not have this effect (all P values are all greater than 0.05), referring to accompanying drawing 4 and Fig. 5.
In accompanying drawing 5 and Fig. 6: L-NNA is the nitric oxide synthase inhibitor activity experimental group; MB is the methylene blue experimental group; Prop is the propranolol experimental group; Indo is the indomethacin experimental group; Denu is for dispeling the coronary artery endothelial experimental group.
4, the propolis water extract is to the inhibitory action of potassium chloride concentration dependency shrinkage curve
Successively the concentration of potassium chloride by 4-100mM is added the coronary blood pipe ring hatched 90 minutes in bathing pipe after, obtain potassium chloride dose dependent shrinkage curve, fully flushing returns to original state down to tension force then, then propolis water extract (100ug/ml) is added the balneation pipe, again potassium chloride is added successively by 4-100mM concentration again after 20 minutes.For comparing with experimental result, other establishes the blank experimental group, promptly adds another with the equivalent normal saline under condition of equivalent and organizes crown blood arterial ring.The result shows that the propolis water extract can significantly suppress the inhibition curve of potassium chloride.The EC50 value of potassium chloride curve is that (n=8, control), the EC50 value of the potassium chloride curve after propolis water extract (100ug/ml) suppresses is that (n=8, p＜0.05vs.control) is referring to accompanying drawing 6 for (93.12 ± 1.21) mM to (16.07 ± 1.42) mM.
In the accompanying drawing 7: KCl is the potassium chloride shrinkage curve; KCl+WEP is for successively adding the shrinkage curve of propolis and potassium chloride; NS is the curve of blank.
6, the propolis water extract is to the inhibitory action of calcium chloride concentration dependency shrinkage curve
The coronary artery ring places no calcium Krebs liquid, wherein contains the EGTA of 0.1mM, adds potassium chloride (80mM) after hatching 90 minutes, adds by 10 successively after 15 minutes
-5-10
-2The calcium chloride of M obtains calcium chloride dose dependent shrinkage curve, and then fully flushing is tried the coronary vasodilator ring, so that its tension force returns to original state, again propolis water extract (100ug/ml) is added the balneation pipe, again calcium chloride is pressed 10 after 20 minutes
-5～10
-2The concentration of M adds again successively.For comparing with experimental result, for comparing with experimental result, other establishes the blank experimental group, promptly adds another with the equivalent normal saline under condition of equivalent and organizes crown blood arterial ring.Experimental result shows that the propolis water extract can significantly suppress the inhibition curve of calcium chloride.The EC50 value that calcium chloride suppresses curve is (3.76 ± 0.58) * 10
-3(n=8, control), the EC50 value of the potassium chloride curve after propolis water extract (100ug/ml) suppresses is (7.98 ± 1.24) * 10 to M
-3M (n=8, p＜0.05vs.control), ginseng accompanying drawing 7.
In the accompanying drawing 7: Calcium is the calcium chloride shrinkage curve; Calcium+WEP is for successively adding the shrinkage curve of propolis and potassium chloride; NS is the curve of blank.
Because the propolis extract of the present invention diastole effect good to coronary artery, therefore propolis extract of the present invention has manifested the good prospect of the medicine that can be used as treatment coronary heart disease.So the application prospect of propolis water extract is widely, be huge particularly to its value on the therapeutic use of coronary heart disease.Women's cause of coronary heart disease after menopause significantly rises in addition, and estrogenic alternative medicine can obviously reduce its sickness rate, but women's breast tumor sickness rate is improved.The phytoestrogen of available technology adopting but can be avoided this harmful effect.The propolis water-soluble flavone class material that the present invention extracts from propolis extract, this type of material is the material with estrogen-like effects equally, so the present invention provides new production approach and the new raw material of a class for the preparation of plant estrogens medicine.
Claims (4)
1, the extracting method of active ingredient in a kind of propolis is characterized in that the propolis water is extracted.
2, method according to claim 1 is characterized in that propolis is pulverized, and water extracts again, and extracting solution is got its supernatant through centrifugal or abundant post precipitation, again with the supernatant lyophilizing.
3, method according to claim 1 and 2 is extracted the application of product in preparation coronary artery diastole medicine.
4, extract the application of product in preparation plant estrogens medicine according to claim 1 or described method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100258363A CN1290518C (en) | 2004-01-08 | 2004-01-08 | Extracting method of propolis effective component and its use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100258363A CN1290518C (en) | 2004-01-08 | 2004-01-08 | Extracting method of propolis effective component and its use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1555814A true CN1555814A (en) | 2004-12-22 |
| CN1290518C CN1290518C (en) | 2006-12-20 |
Family
ID=34352215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100258363A Expired - Fee Related CN1290518C (en) | 2004-01-08 | 2004-01-08 | Extracting method of propolis effective component and its use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1290518C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005031361A1 (en) * | 2005-06-30 | 2007-01-04 | Biotronik Vi Patent Ag | Use of propolis as a coating material for medical implants |
| CN102078337A (en) * | 2011-01-14 | 2011-06-01 | 哈药集团密山蜂业有限公司 | Propolis natural reduction extraction process method |
| CN103125802A (en) * | 2013-03-11 | 2013-06-05 | 宁夏原野蜂业有限公司 | Nutrition taking propolis cream, medlar cream, honey and desert ginseng powder as raw materials and preparation method of nutrition |
| CN104557520A (en) * | 2015-01-21 | 2015-04-29 | 聊城大学 | Method for separating and purifying caffeic acid, ferulic acid and isoferulic acid from Chinese propolis aqueous extract |
-
2004
- 2004-01-08 CN CNB2004100258363A patent/CN1290518C/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005031361A1 (en) * | 2005-06-30 | 2007-01-04 | Biotronik Vi Patent Ag | Use of propolis as a coating material for medical implants |
| CN102078337A (en) * | 2011-01-14 | 2011-06-01 | 哈药集团密山蜂业有限公司 | Propolis natural reduction extraction process method |
| CN103125802A (en) * | 2013-03-11 | 2013-06-05 | 宁夏原野蜂业有限公司 | Nutrition taking propolis cream, medlar cream, honey and desert ginseng powder as raw materials and preparation method of nutrition |
| CN104557520A (en) * | 2015-01-21 | 2015-04-29 | 聊城大学 | Method for separating and purifying caffeic acid, ferulic acid and isoferulic acid from Chinese propolis aqueous extract |
| CN104557520B (en) * | 2015-01-21 | 2016-01-13 | 聊城大学 | A method for separating and purifying caffeic acid, ferulic acid and isoferulic acid from Chinese propolis water extract |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1290518C (en) | 2006-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pitchaipillai et al. | In vitro antidiabetic activity of ethanolic leaf extract of bruguiera Cylindrica L.–glucose uptake by yeast cells method | |
| JP2006512330A (en) | Preparation and use of triterpenoid sapogenin compounds extracted from bamboo | |
| AU2021469614A1 (en) | Use of composition comprising astilbin and/or isomer thereof in preparation of drug for treating psoriasis | |
| Liu et al. | Saponins of Momordica charantia increase insulin secretion in INS-1 pancreatic β-cells via the PI3K/Akt/FoxO1 signaling pathway | |
| JP2016522227A (en) | Methods for obtaining plant extracts and related compositions | |
| WO2008009084A1 (en) | Preparation and pharmaceutical use of euterpe oleracea (acai) extract compositions | |
| TW201618801A (en) | Pharmaceutical composition for adjuvant chemotherapy drugs and use thereof | |
| US8945633B2 (en) | Pharmaceutical composition for preventing and treating inflammatory diseases containing an ethyl acetate fraction of dried extract of Trachelospermi caulis as an active ingredient, and method for producing the fraction | |
| CN1290518C (en) | Extracting method of propolis effective component and its use | |
| CN106632718B (en) | Preparation method of white and polysaccharide | |
| CN109232757B (en) | Walnut leaf polysaccharide extract and application | |
| CN1568929A (en) | Cosmetics containing humic acid and application of humic acid in cosmetics | |
| CN109689064B (en) | Composition for wound treatment containing Uldavioside A compound | |
| JP6469518B2 (en) | Angiogenesis promoter | |
| CN112062870B (en) | Polysaccharide with whitening and moisturizing activities, whitening and moisturizing cream containing polysaccharide and preparation method of whitening and moisturizing cream | |
| CN109364290A (en) | A kind of Lavender liposome liquid adhesive bandage and preparation method thereof | |
| CN111150754B (en) | Application of chestnut flower extract in preparation of food or anti-inflammatory drug | |
| TW201343173A (en) | Use of a pharmaceutical composition for promoting wound healing and a plant of the genus Sambucus or Isatis for preparing a medicine for promoting wound healing | |
| CN108478540B (en) | A kind of preparation method of Tripterygium wilfordii sustained-release microcapsules | |
| FR3132632A1 (en) | Composition comprising an extract of myrtle and an extract of Tripterygium wilfordii to fight acne in non-lesional areas of acne-prone skin | |
| Abdelgawad et al. | Rams (Haloxylon salicornicum) Powder and Extract in Diets of Male Albino Rats to Cope Hyperglycemia | |
| Siddiqui | Green papaya as a potential source for diabetic and diabetic-wound healing therapy | |
| Chitravel et al. | Antidiabetic potential of Biophytum sensitivum whole plant extracts in STZ induced diabetic rats | |
| KR20190119020A (en) | A composition for anti-inflammation comprising hemistepta lyrata extract | |
| CN119700806B (en) | Anti-depression compound traditional Chinese medicine and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061220 Termination date: 20100108 |